Pubdate: Mon, 16 Apr 2012
Source: Evening Standard (London, UK)
Copyright: 2012 Associated Newspapers Ltd.
Contact:  http://www.thisislondon.co.uk/
Details: http://www.mapinc.org/media/914

CANNABIS CANCER TRIAL PAYMENT FOR GW

GW Pharmaceuticals is to pocket an =8011.9 million
(UKP9.7 million) payment after its cannabis-based
medicine Sativex reached the target number of
patients needed for a cancer pain trial
programme. The payment - by Spanish drugmaker
Almirall - comes after GW successfully bought
Sativex onto the market as a prescription medicine for MS sufferers.
- ---
MAP posted-by: Jay Bergstrom